⌘K

Holding(s) in Company

RNS Number : 9494U

Allergy Therapeutics PLC

28 November 2023

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:			Allergy Therapeutics plc Company number: 05141592 Dominion Way, Worthing, West Sussex, BN14 8SA
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name			Abbott Laboratories, an Illinois corporation
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)
Name			Yissum Holding Limited
City and country of registered office (if applicable)			Valletta, Malta
Name			Abbott Laboratories (Chile) Holdco SpA
City and country of registered office (if applicable)			Santiago, Chile
5. Date on which the threshold was crossed or reached:			09/11/2023
6. Date on which issuer notified (DD/MM/YYYY):			14/11/2023
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B)
Resulting situation on the date on which threshold was crossed or reached	Below 3%	N/A		Below 3%	0
Position of previous notification (if applicable)	5.06%	N/A		5.06%	240,584,571

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
N/A		0		0			0%		0%

SUBTOTAL 8. A

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date	Exercise/ Conversion Period			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights


			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash Settlement			Number of voting rights	% of voting rights

					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)
Name	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold



10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information

Place of completion	Chicago, Illinois, United States of America
Date of completion	14/11/2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLUWVSROWUAUAA

Holding(s) in Company - Allergy Therapeutics PLC | RNS | Ticker